Evidence map›Paper›PMID 22364280›Full record

ReviewThe Biochemical journal2012

Cell signalling by reactive lipid species: new concepts and molecular mechanisms.

Ashlee Higdon, Anne R Diers, Joo Yeun Oh, Aimee Landar, Victor M Darley-Usmar

Open access · bronzeAbstract readReview
In one paragraph

Review in The Biochemical journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 306 citations in OpenAlex.

  1. Trial
  2. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2021
    Trial
  3. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2020
    Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Yin-Dan-Ping-Gan Capsule Mitigates CCLPharmaceuticals (Basel, Switzerland) · 2026
    Article
  11. Neuroprotective Effects ofArchives of Razi Institute · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Iron and Cell Death.Advances in experimental medicine and biology · 2025
    Review
  19. Article
  20. Heavy metals, oxidative stress, and the role of AhR signaling.Toxicology and applied pharmacology · 2024
    Review

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ashlee HigdonDepartment of Pathology, Center for Free Radical Biology, University of Alabama at Birmingham, 35294, USA.
Anne R Diers
Joo Yeun Oh
Aimee Landar
Victor M Darley-Usmar
University of Alabama at Birmingham · US

Funding

Ethanol toxicity and NO-dependent mitochondrial damageR01AA013395 · NIAAA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DARLEY-USMAR, VICTOR M · 2002 to 2011
$2.9M
INDUCTION OF ANTIOXIDANT DEFENSES BY OXIDIZED LIPIDSR01ES010167 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DARLEY-USMAR, VICTOR M · 2000 to 2009
$2.1M
The role of the mitochondrial protein thiol modification in endothelial dysfunctiR01HL096638 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LANDAR, AIMEE LEIGH · 2010 to 2014
$1.8M
ACTIVE MOMS: Physical Activity Intervention for Women with Gestational DiabetesR21DK075867 · NIDDK · PENNSYLVANIA STATE UNIVERSITY, THE · PI DOWNS, DANIELLE SYMONS · 2006 to 2007
$393k
NHLBI NIH HHS HL007918NHLBI NIH HHS HL096638NHLBI NIH HHS R01 HL096638NIAAA NIH HHS AA13395NIDDK NIH HHS DK075867NIEHS NIH HHS ES10167
6 · The paper itself

Abstract

The process of lipid peroxidation is widespread in biology and is mediated through both enzymatic and non-enzymatic pathways. A significant proportion of the oxidized lipid products are electrophilic in nature, the RLS (reactive lipid species), and react with cellular nucleophiles such as the amino acids cysteine, lysine and histidine. Cell signalling by electrophiles appears to be limited to the modification of cysteine residues in proteins, whereas non-specific toxic effects involve modification of other nucleophiles. RLS have been found to participate in several physiological pathways including resolution of inflammation, cell death and induction of cellular antioxidants through the modification of specific signalling proteins. The covalent modification of proteins endows some unique features to this signalling mechanism which we have termed the 'covalent advantage'. For example, covalent modification of signalling proteins allows for the accumulation of a signal over time. The activation of cell signalling pathways by electrophiles is hierarchical and depends on a complex interaction of factors such as the intrinsic chemical reactivity of the electrophile, the intracellular domain to which it is exposed and steric factors. This introduces the concept of electrophilic signalling domains in which the production of the lipid electrophile is in close proximity to the thiol-containing signalling protein. In addition, we propose that the role of glutathione and associated enzymes is to insulate the signalling domain from uncontrolled electrophilic stress. The persistence of the signal is in turn regulated by the proteasomal pathway which may itself be subject to redox regulation by RLS. Cell death mediated by RLS is associated with bioenergetic dysfunction, and the damaged proteins are probably removed by the lysosome-autophagy pathway.

Indexed as

Signal TransductionAnimalsAutophagyCell DeathHumansLipid MetabolismLipid PeroxidationOxidation-ReductionStress, Physiological

Identifiers

PMID22364280
PMCPMC3286857
OpenAlexW2153819462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.